Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Cash from Financing Activities (2016 - 2025)

United Therapeutics (UTHR) has disclosed Cash from Financing Activities for 17 consecutive years, with $98.4 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 231.73% to $98.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.2 billion through Dec 2025, up 8.35% year-over-year, with the annual reading at -$1.2 billion for FY2025, 8.35% up from the prior year.
  • Cash from Financing Activities hit $98.4 million in Q4 2025 for United Therapeutics, up from -$956.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $98.4 million in Q4 2025 to a low of -$1.1 billion in Q1 2024.
  • Historically, Cash from Financing Activities has averaged -$114.8 million across 5 years, with a median of $7.2 million in 2021.
  • Biggest five-year swings in Cash from Financing Activities: surged 640.0% in 2022 and later plummeted 2297.53% in 2024.
  • Year by year, Cash from Financing Activities stood at $7.5 million in 2021, then soared by 640.0% to $55.5 million in 2022, then crashed by 267.21% to -$92.8 million in 2023, then grew by 19.5% to -$74.7 million in 2024, then surged by 231.73% to $98.4 million in 2025.
  • Business Quant data shows Cash from Financing Activities for UTHR at $98.4 million in Q4 2025, -$956.0 million in Q3 2025, and -$198.6 million in Q2 2025.